白细胞介素2激活骨髓抗骨髓瘤活性的研究

Study of antimyeloma activity of interleukin-2 activated bone marrow in vitro

目的 探讨重组白细胞介素2(rIL 2)激活的骨髓(ABM)抗骨髓瘤活性的免疫学机制。方法 应用rIL 2体外分别激活多发性骨髓瘤(MM)患者骨髓及正常对照骨髓,同时设未激活骨髓(NBM)为对照。用MTT比色分析法测定正常对照组的ABM对U266细胞的杀伤活性,应用流式细胞仪检测培养72h后MM组骨髓瘤残余病变标志(CD45-CD38+CD138+细胞百分率)的变化,ELISA法检测MM组及正常对照组不同时间段ABM、NBM培养液中TNF α、IFN γ的水平,并进行比较和相关性分析。结果 正常对照组NBM 72h对U266细胞的杀伤率为( 43. 20±12. 39 )%, 24h杀伤率为(26. 53±5. 48)%,ABM 72h对U266细胞的杀伤率为( 69. 70±26. 57 )%, 24h杀伤率为( 34. 25±11. 93)%, 24h及72h的ABM细胞杀伤活性均较NBM增高,其中72hABM与NBM对U266细胞杀伤率的差异有统计学意义(P<0. 05);MM患者骨髓经rIL 2激活72h后CD45-CD38+CD138+细胞的百分率明显下降[激活前为(8. 46±3. 66)%,激活后为(4. 79±1. 56)%, P<0. 05];正常骨髓及MM患者骨髓经rIL 2激活后,随着培养时间的延长,培养液中TNF α、IFN γ的含量增加,无论24h或72h,两组ABM中TNF α、IFN γ的水平均较NBM明显增高(P<0. 05);正常对照组ABM 24h及72h培养液中TNF α、IFN

Objective To study the antimyeloma activity of interleukin-2 activated bone marrow (ABM) . Methods Bone marrow mononuclear cells (BMMNC) from multiple myeloma and iron-deficiency anemia patients were cultured in the presence of rIL-2. The antimyeloma activity of ABM against U266 cells, cells expressing surface CD45,CD38,CD138, the levels of TNF-α and IFN-γ in ABM culture supernatant were measured with MTT method,flow cytometry and ELISA method respectively after bone marrow was activated with rIL-2 for 24 and 72 hours. Results The tumor-killing activities against U266 cells of ABM were significantly increased compared with that of non-activated bone marrow (NBM) at 72 hours \[(69.70± 26.57 )% vs (43.20±12.39)%,P<0.05\] and 24 hours \[(34.25±11.93)% vs (26.53±5.48)%\]. The CD45 - CD38 + CD138 + cells of ABM from myeloma group at 72 hours were decreased from (8.46± 3.66 )% to ( 4.79 ±1.56)%(P<0.05). TNF-α and IFN-γ were detectable after cultured for 24 hours in both normal control group and myeloma group and went higher at 72 hours. The level of TNF-α and IFN-γ were significantly increased in ABM compared with that in NBM (P<0.05). Meanwhile,there was a positive relationship between the level of TNF-α、IFN-γ and cytotoxicity of ABM from normal control group at 24 hours and 72 hours (P<0.05), and was a negative relationship between TNF-α and IFN-γ levels and the CD45 -CD38 +CD138 + cells in myeloma group at 72 hours (P<0.05). Conclusion Normal BMMNCs activated with rIL-2 have tumor-killing activities against U266 cells. Myeloma cells and tumor burden were decreased in myeloma bone marrow after the marrow was activated with rIL-2. Production of TNF-α and IFN-γ from bone marrow cells including T cells, monocyte-macrophags and NK cells activated with rIL-2 might be involved in antimyeloma activity of ABM.